Community update Biogen: salanersen (BIIB115) Study
We are pleased to share a community letter Biogen, announcing topline results from the Phase 1 study of salanersen (BIIB115) for SMA.
Biogen's early Phase 1 results for salanersen, a modified ASO similar to nusinersen, show it’s well tolerated and may reduce nerve damage in children with SMA. Phase 3 planning is underway.